Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045043 · ClinicalTrials.gov registry record
Genetic Risk Assessment of Defibrillator Events
A clinical trial, sponsored by University of Iowa.
- Completed
- Registry status
- 1,807
- Enrollment target
NCT02045043: Completed study, sponsored by University of Iowa.
NCT02045043 is a clinical trial that has completed, run by University of Iowa. The registered enrollment target is 1,807 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02045043 has completed, sponsored by University of Iowa.
- COMPLETED
- Registry status
- 1,807 participants
- Enrollment target
Study Summary
Arrhythmias remain a major health problem, causing at least 250,000 deaths annually in the United States. Pharmacological treatments often do more harm than good, and device therapies are limited by high cost and effects on quality of life. Ion channel mutations cause rare inherited arrhythmopathies, but account for only a small fraction of patients with life- threatening arrhythmias and sudden death. Most arrhythmias occur during myocardial ischemia, following myocardial infarction, and in patients with poor left ventricular (LV) function of any etiology. Aside from ejection fraction (EF), few clinically useful indicators to stratify the risk of sudden death have been identified. The role of subtle difference in ion channel expression and/or structure in predisposing patients to arrhythmias and modulating the risk of sudden death is unknown. In this study, we are prospectively testing whether polymorphisms in ion channels and ion channel modifying genes are associated with arrhythmias in a population with internal cardioverter-defibrillators (ICDs) and poor LV function. We will test the hypothesis that functional polymorphisms in the coding sequences and promoter regions of cardiac genes (e.g. ion channels, beta-adrenergic receptors) predispose individuals to arrhythmias and /or heart failure progression. We hope to identify genetic predictors for the common forms of sudden cardiac death. This would allow the identification of a subpopulation of heart failure patients that would benefit most from ICD placement.
Primary Outcome
Time to first appropriate shock from an Implantable Cardioverter-Defibrillator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,807 participants |
| Start Date | 2002-03 |
| Est. Completion | 2012-06 |
What the finished NCT02045043 record still lists
NCT02045043 is an observational study that tracks outcomes without assigning an intervention. Its 1,807 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT02045043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02045043 about?
NCT02045043 is a clinical study titled "Genetic Risk Assessment of Defibrillator Events". Arrhythmias remain a major health problem, causing at least 250,000 deaths annually in the United States. Pharmacological treatments often do more harm than good, and device therapies are limited by high cost and effects on quality of life. Ion channel mutations cause rare inherited arrhythmopathies...
What is the current status of trial NCT02045043?
This trial is currently completed. The enrollment target is 1,807 participants. The study started on 2002-03. Estimated completion is 2012-06.
Who is sponsoring clinical trial NCT02045043?
This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia